国际儿童糖尿病登记SWEET研究:胰岛素泵与葡萄糖传感器使用与血糖结局的关联
该研究基于国际SWEET登记系统,纳入25654例1型糖尿病儿童及青少年,按胰岛素泵和传感器使用情况分为四组,分析HbA1c、DKA和严重低血糖比例。结果显示使用泵和/或传感器者HbA1c更低,泵联合传感器者DKA比例更低,泵使用者严重低血糖比例更低。
要点
- 使用胰岛素泵和/或传感器者HbA1c均低于仅注射无传感器者。
- 泵联合传感器者DKA比例低于仅注射无传感器者。
- 泵使用者严重低血糖比例更低,但注射加传感器者严重低血糖比例更高。
核心结论
- 使用胰岛素泵或持续葡萄糖监测(CGM)或两者联用者HbA1c更低且DKA发作更少。
- 泵使用与严重低血糖发生率更低相关。
- 泵与CGM联用与额外获益相关。
研究设计与样本
- 国际多中心SWEET登记研究,纳入1型糖尿病≥1年、年龄≤18岁、2017年8月至2019年7月有泵或传感器使用记录的儿童及青少年。
- 共分析25654例参与者,按治疗方式分为四组:仅注射无传感器(参照组)、注射加传感器、泵无传感器、泵加传感器。
- 采用线性与逻辑回归模型,校正人口学、地区及人均GDP。
主要发现
- 各组调整后HbA1c:仅注射无传感器组37.44%的参与者HbA1c为8.72%(95%CI 8.68-8.75);注射加传感器组14.98%为8.30%(95%CI 8.25-8.35);泵无传感器组17.22%为8.07%(95%CI 8.03-8.12);泵加传感器组30.35%为7.81%(95%CI 7.77-7.84)。
- 所有使用泵和/或传感器的组别HbA1c均低于仅注射无传感器组(P < 0.001)。
- DKA比例:泵加传感器组1.98%(95%CI 1.64-2.48;P < 0.001)和泵无传感器组2.02%(95%CI 1.64-2.48;P < 0.05)均低于仅注射无传感器组2.91%(95%CI 2.59-3.31)。
- 严重低血糖比例:泵无传感器组1.10%(95%CI 0.85-1.43;P < 0.001)低于仅注射无传感器组2.35%(95%CI 2.04-2.71);注射加传感器组4.25%(95%CI 3.65-4.95;P < 0.001)高于仅注射无传感器组。
临床怎么用
- 在1型糖尿病儿童及青少年中,使用胰岛素泵和/或CGM与更低的HbA1c相关,泵联合CGM可能带来额外获益。
- 泵使用与严重低血糖风险更低相关,但注射联合传感器者需关注严重低血糖风险。
- SWEET中心中泵和CGM的使用呈增加趋势。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Insulin delivery methods, glucose-monitoring modalities, and related outcomes were examined in a large, international, diverse cohort of children and adolescents with type 1 diabetes from the Better Control in Pediatric and Adolescent Diabetes: Working to Create Centers of Reference (SWEET) -Registry. RESEARCH DESIGN AND METHODS: Participants with type 1 diabetes of ≥1 year, aged ≤18 years, and who had documented pump or sensor usage during the period August 2017-July 2019 were stratified into four categories: injections-no sensor (referent); injections + sensor; pump-no sensor; and pump + sensor. HbA1c and proportion of patients with diabetic ketoacidosis (DKA) or severe hypoglycemia (SH) were analyzed; linear and logistic regression models adjusted for demographics, region, and gross domestic product per capita were applied. RESULTS: Data of 25,654 participants were analyzed. The proportions of participants (adjusted HbA1c data) by study group were as follows: injections-no sensor group, 37.44% (8.72; 95% CI 8.68-8.75); injections + sensor group, 14.98% (8.30; 95% CI 8.25-8.35); pump-no sensor group, 17.22% (8.07; 95% CI 8.03-8.12); and pump + sensor group, 30.35% (7.81; 95% CI 7.77-7.84). HbA1c was lower in all categories of participants who used a pump and/or sensor compared with the injections-no sensor treatment method (P < 0.001). The proportion of DKA episodes was lower in participants in the pump + sensor (1.98%; 95% CI 1.64-2.48; P < 0.001) and the pump-no sensor (2.02%; 95% CI 1.64-2.48; P < 0.05) groups when compared with those in the injections-no sensor group (2.91%; 95% CI 2.59-3.31). The proportion of participants experiencing SH was lower in pump-no sensor group (1.10%; 95% CI 0.85-1.43; P < 0.001) but higher in the injections + sensor group (4.25%; 95% CI 3.65-4.95; P < 0.001) compared with the injections-no sensor group (2.35%; 95% CI 2.04-2.71). CONCLUSIONS: Lower HbA1c and fewer DKA episodes were observed in participants using either a pump or continuous glucose monitoring (CGM) or both. Pump use was associated with a lower rate of SH. Across SWEET centers, use of pumps and CGM is increasing. The concomitant use of pump and CGM was associated with an additive benefit.
引用
- Cardona-Hernandez R, Schwandt A, Alkandari H, et al. Glycemic Outcome Associated With Insulin Pump and Glucose Sensor Use in Children and Adolescents With Type 1 Diabetes. Data From the International Pediatric Registry SWEET. Diabetes Care. 2021. PMID: 33653821. doi:10.2337/dc20-1674
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。